PUBLICATIONS

• Shandil R K, Dhup S, Narayanan S, Evaluation of the Therapeutic Potential of Mesenchymal Stem Cells (MSCs) in Preclinical Models of Autoimmune Diseases Stem Cells International 2022 https://doi.org/10.1155/2022/6379161

​

• Prabhu P, Fernandes T, Damani M, Chaubey P, Narayanan S, Sawarkar S. 2Receptor Specific Ligand conjugated Nanocarriers: an Effective Strategy for Targeted Therapy of Tuberculosis. Curr Drug Deliv. 2021 Dec 16. https://doi.org/10.2174/1567201819666211216141942  

​

• Chandrasekaran Padmapriydarsini, Megha Mamulwar, Anant Mohan, Prema Shanmugam, N S Gomathy, Aarti Mane, Urvashi B Singh, Nathella Pavankumar, Abhijeet Kadam, Hemanth kumar, Chandra Suresh, Devaraju Reddy, Poornaganga Devi, P M Ramesh, Lakshmanan Sekar, Shaheed Jawahar, R K Shandil, Manjula Singh, Jaykumar Menon, Randeep Guleria, METRIF Team, Randomized trial of Metformin with Anti-tuberculosis drugs For Early Sputum Conversion in Adults with Pulmonary Tuberculosis, Clinical Infectious Diseases, 2021;  https://doi.org/10.1093/cid/ciab964 

​

• Kaur P, Potluri V, Ahuja VK, Naveenkumar CN, Krishnamurthy RV, Gangadharaiah ST, Shivarudraiah P, Eswaran S, Nirmal CR, Mahizhaveni B, Dusthackeer A, Mondal R, Batt SM, Richardson EJ, Loman NJ, Besra GS, Shandil RK, Narayanan S. A multi-targeting pre-clinical candidate against drug-resistant tuberculosis. Tuberculosis (Edinb). 2021 Jun 18;129:102104. https://doi.org/10.1016/j.tube.2021.102104  

 

• Narayanan S, Shandil RK, Ahuja VK, Shanmugam SS, Mahesh K U H, Ramesh N, Surendran N. Development and validation of LC/MS/MS method for Triciribine and its monophosphate metabolite in plasma and RBC: Application to mice pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Jun 1;1174:122714 https://doi.org/10.1016/j.jchromb.2021.122714

 

• Vijay P, Radha K S, Gavara R, Ganesh S, Brice C, Sergio W and Shridhar N. Discovery of FNDR-20123, a histone deacetylase inhibitor for the treatment of Plasmodium falciparum malaria. Malaria Journal. 2020. 19:365 https://doi.org/10.1186/s12936-020-03421-3

 

• Balachandra B, Radha K S, Jagadeesh B and Tanjore S B. Two Decades of TB Drug Discovery Efforts—What Have We Learned? Applied Sciences. 2020. 10, 5704; https://doi.org/10.3390/app10165704

​

• Pradeep A S, Neha V S, Seetha S, Pallavi M, Bhavana N, Sushrut D, Sowmya K B, Devaiah M K, Ramya V K, Benudhar M, Priyasha M, Noriko Y, Susanta K G, Radha K S, Shridhar N, Brice C, Kouichi H, Anupkumar R A, Neena V and Varadharajan S. Plasmodium vivax liver stage assay platforms using Indian clinical isolates. Malaria Journal. 2020. 19:214 https://doi.org/10.1186/s12936-020-03284-8

 

• Richa M, Sakshi K, Nitish M, Parijat B, Mansi M, MohamedHusen M, Vasista , Vijay K A, Radha K , Raju S R, Aswin S N S, Amit S. Targeting redox heterogeneity to counteract drug tolerance in replicating Mycobacterium tuberculosis. Sci. Transl. Med. 2019. 11: eaaw6635.  https://doi.org/10.1126/scitranslmed.aaw6635

 

• Manjunatha M R,  Radha K S, Manoranjan P, Claire S, Anisha A, Vijender P, Naveen K, Jyothi M, Sreenivasaiah M,Ashwini N, Supreeth G, Sreevalli S, Vasan K S, Vasanthi R, Meenakshi M, Christopher C, Khisi M, Scott B, Ruben T,Pravin S I, Shridhar N, Monalisa C, and Pravin S S. Scaffold Morphing to Identify Novel DprE1 Inhibitors with Antimycobacterial Activity: ACS Med Chem. 2019. https://doi.org/10.1021/acsmedchemlett.9b00343

 

• Shruthi T G, Eswaran S, Shivarudraiah P, Narayanan S, Subramanian S. Synthesis, antituberculosis studies and biological evaluation of new quinoline derivatives carrying 1,2,4-oxadiazole moiety. Bioorg Med Chem Lett. 2019. 29(1):97-102. PubMed PMID: 30448235. https://doi.org/10.1016/j.bmcl.2018.11.002

 

• Tantry S J, Markad S D, Shinde V, Bhat J, Balakrishnan G, et al. Discovery of Imidazo[1,2-a]pyridine Ethers and Squaramides as Selective and Potent Inhibitors of Mycobacterial Adenosine Triphosphate (ATP) Synthesis. J Med Chem. 2017. 60 (4):1379-1399. PubMed PMID: 28075132. https://doi.org/10.1021/acs.jmedchem.6b01358